We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biopharmaceutical firm Parvus Therapeutics has signed a worldwide collaboration and licence agreement with Genentech to develop, manufacture and commercialise therapeutics for inflammatory bowel disease (IBD), autoimmune liver diseases (ALD) and coeliac d